Lixte Biotechnology Holdings LIXT 深 滬
等待開盤 10-25 09:30:00 美东时间
4.33
0.000
0.00%
華盛通- 最 高4.41
- 今 開4.33
- 成交量 4.41万股
- 最 低 4.25
- 昨 收 4.33
- 總市值 1975.09万
- 52周最高 6.26
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 0.64
- 委 比 -94.38%
- 總股本 456.14万
- 歷史最高 71.90
- 量 比 0.47
- 振 幅 3.70%
- 歷史最低 0.64
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings, Inc. announced its Q4 2025 priorities, including advancing its lead compound LB-100, pursuing acquisitions of complementary oncology assets, and enhancing operational readiness. The company is in advanced negotiations for potential transactions aligned with its strategic goals.
10-16 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Lixte Biotechnology Invests $2.6M in Cryptocurrencies
The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). O...
09-12 01:47
LIXTE Biotechnology makes $2.6M initial purchase of digital currency
LIXTE Biotechnology (NASDAQ:LIXT) said on Wednesday that it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The company purc...
09-11 04:17
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
LIXTE Biotechnology Holdings, Inc. ("LIXTE") announced the purchase of 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) totaling approximately $2.6 million to diversify its treasury and facilitate potential acquisitions. Cryptocurrency now constitutes about 43.6% of LIXTE's treasury holdings, with the Board approving up to 50% allocation to digital assets. CEO Geordan Pursglove emphasized the strategic importance of integrating cryptocurrencies to enhan...
09-10 20:05
Lixte Biotechnology appoints new CFO and board members
Lixte Biotechnology (NASDAQ:LIXT) appointed Peter Stazzone as chief financial officer. Lourdes Felix and Guy Primus joined LIXTE’s board of directors. Former CFO Robert Weingarten and board members Ba...
09-03 20:18
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
LIXTE Biotechnology Holdings announced the addition of Peter Stazzone as Chief Financial Officer and Lourdes Felix and Guy Primus to its Board of Directors, succeeding Bas van der Baan and René Bernards. The company has relocated its headquarters to Boca Raton, Florida, aiming to enhance operational efficiency and reduce costs. Stazzone brings over 20 years of financial management experience, while Felix and Primus add expertise in corporate fina...
09-03 12:00
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
LIXTE Biotechnology Holdings, Inc. is advancing its lead compound, LB-100, in clinical trials targeting MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma. LB-100 aims to enhance chemotherapy and immunotherapy effectiveness. Trials in MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma are ongoing, with interim data expected soon. The company focuses on high-need cancer indications via combinatio...
08-25 12:05
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
LIXTE Biotechnology’s lead compound LB-100, a first-in-class PP2A inhibitor, is highlighted in a Nature Reviews Cancer editorial for its innovative approach to cancer therapy. Unlike traditional methods, LB-100 hyperactivates oncogenic pathways, pushing cancer cells into a stress-induced collapse, and has shown promise in preclinical and clinical studies, including tumor regression in colorectal and pancreatic models. The compound’s mechanism, wh...
08-19 15:18
LIXTE Biotechnology Holdings Provides Corporate Update
LIXTE Biotechnology Holdings, Inc. has completed two financings, raising $6.5 million, and regained compliance for continued listing on Nasdaq. The company appointed Geordan Pursglove as Chairman and CEO, and Bas van der Baan as President and Chief Scientific Officer. Two new board members, Jason Sawyer and Michael Holloway, MD, were added. LIXTE’s compound LB-100 received validation through a study published in *Nature*, showing improved surviva...
08-18 12:00
